Patent · US Active

Monoclonal antibodies with enhanced ADCC function

US9718889B2 · kind B2 · utility

1Cited by

15References

27Claims

0Family size

Assignee

Laboratoire Francais du Fractionnement et des Biotechnologies · FR

Inventors

Roland Beliard · Santes, FR
Dominique Bourel · La Madeleine, FR
Amaud Glacet · Gondecourt, FR
Christophe de Romeuf · Lambersart, FR
Nicolas Bihoreau · Orsay, FR
Emmanuel Nony · Antony, FR

Key dates

Filing date	Feb 9, 2015
Grant date	Aug 1, 2017
Priority date	—
Expiry date	Feb 9, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.